BioLineRx Statistics
Total Valuation
BioLineRx has a market cap or net worth of $16.83 million. The enterprise value is $3.31 million.
Important Dates
The last earnings date was Tuesday, May 27, 2025, before market open.
Earnings Date | May 27, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
BioLineRx has 2.23 billion shares outstanding. The number of shares has increased by 47.46% in one year.
Current Share Class | n/a |
Shares Outstanding | 2.23B |
Shares Change (YoY) | +47.46% |
Shares Change (QoQ) | +69.54% |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | n/a |
Float | 2.13B |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 0.75 |
Forward PS | n/a |
PB Ratio | 0.81 |
P/TBV Ratio | 1.61 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 0.15 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.27, with a Debt / Equity ratio of 0.66.
Current Ratio | 2.27 |
Quick Ratio | 2.02 |
Debt / Equity | 0.66 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -1.95 |
Financial Efficiency
Return on equity (ROE) is -20.03% and return on invested capital (ROIC) is -35.44%.
Return on Equity (ROE) | -20.03% |
Return on Assets (ROA) | -21.98% |
Return on Invested Capital (ROIC) | -35.44% |
Return on Capital Employed (ROCE) | -56.72% |
Revenue Per Employee | $797,857 |
Profits Per Employee | -$121,357 |
Employee Count | 28 |
Asset Turnover | 0.47 |
Inventory Turnover | 2.53 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -84.15% in the last 52 weeks. The beta is 0.86, so BioLineRx's price volatility has been lower than the market average.
Beta (5Y) | 0.86 |
52-Week Price Change | -84.15% |
50-Day Moving Average | 3.25 |
200-Day Moving Average | 10.73 |
Relative Strength Index (RSI) | 64.25 |
Average Volume (20 Days) | 1,916,204 |
Short Selling Information
Short Interest | 181,450 |
Short Previous Month | 198,765 |
Short % of Shares Out | 4.89% |
Short % of Float | n/a |
Short Ratio (days to cover) | 10.35 |
Income Statement
In the last 12 months, BioLineRx had revenue of $22.34 million and -$3.40 million in losses. Loss per share was -$0.00.
Revenue | 22.34M |
Gross Profit | 14.50M |
Operating Income | -16.72M |
Pretax Income | -49.15M |
Net Income | -3.40M |
EBITDA | -14.00M |
EBIT | -16.72M |
Loss Per Share | -$0.00 |
Full Income Statement Balance Sheet
The company has $26.37 million in cash and $13.74 million in debt, giving a net cash position of $12.63 million or $0.01 per share.
Cash & Cash Equivalents | 26.37M |
Total Debt | 13.74M |
Net Cash | 12.63M |
Net Cash Per Share | $0.01 |
Equity (Book Value) | 20.86M |
Book Value Per Share | 0.01 |
Working Capital | 17.89M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$32.36 million and capital expenditures -$21,000, giving a free cash flow of -$32.38 million.
Operating Cash Flow | -32.36M |
Capital Expenditures | -21,000 |
Free Cash Flow | -32.38M |
FCF Per Share | -$0.01 |
Full Cash Flow Statement Margins
Gross margin is 64.90%, with operating and profit margins of -74.85% and -15.21%.
Gross Margin | 64.90% |
Operating Margin | -74.85% |
Pretax Margin | -15.21% |
Profit Margin | -15.21% |
EBITDA Margin | -62.67% |
EBIT Margin | -74.85% |
FCF Margin | n/a |
Dividends & Yields
BioLineRx does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -47.46% |
Shareholder Yield | -47.46% |
Earnings Yield | -20.19% |
FCF Yield | -192.34% |
Analyst Forecast
The average price target for BioLineRx is $19.00, which is 308.16% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $19.00 |
Price Target Difference | 308.16% |
Analyst Consensus | Strong Buy |
Analyst Count | 2 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
The last stock split was on January 30, 2025. It was a reverse split with a ratio of 0.025:1.
Last Split Date | Jan 30, 2025 |
Split Type | Reverse |
Split Ratio | 0.025:1 |
Scores
BioLineRx has an Altman Z-Score of -11.89 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -11.89 |
Piotroski F-Score | 3 |